

Supplementary table 1. Overview of missing values, n (%).

	Overall, n = 108	Remdesivir + SoC, n= 16	SoC, n=27	HCQ + SoC, n = 40	SoC, n = 47
Demographics					
Age, years	0	0	0	0	0
Female, n (%)	0	0	0	0	0
Body Mass Index (kg/m ²)	6 (5.6)	0	2 (7.4)	2 (5.0)	4 (8.5)
Smoking history	4 (3.7)	2 (12.5)	1 (3.7)	0 (0)	2 (4.3)
Comorbidities					
Chronic pulmonary disease	0	0	0	0	0
Hypertension	0	0	0	0	0
Diabetes mellitus	0	0	0	0	0
Obesity (BMI > 30 kg/m ²), n (%)	6 (5.6)	0	2 (7.4)	4 (8.5)	2 (5.0)
Baseline characteristics					
Duration of symptoms prior to baseline (days)	0	0	0	0	0
P/F-ratio (kPa)	1 (0.9)	0	0	1 (2.5)	0
Respiration rate per minute	0	0	0	0	0
Temperature (°C)	0	0	0	0	0
Admission to ward, n (%)	0	0	0	0	0
Admission to ICU, n (%)	0	0	0	0	0
Biochemical presentation					
Haemoglobin (g/dL)	0	0	0	0	0
White blood cell count (x 10 ⁹ per L)	0	0	0	0	0
Lymphocytes (x 10 ⁹ per L)	5 (4.6)	0	2 (7.4)	2 (5.0)	2 (4.3)
Platelet count (x 10 ⁹ per L)	0	0	0	0	0
Creatinine (µmol/L)	1 (0.9)	0	0	1 (2.5)	0
Ferritin (µg/L)	4 (3.7)	0	0	1 (2.5)	3 (6.4)
CRP	0	0	0	0	0

LDH (U/L)	3 (2.8)	0	2 (7.4)	0	3 (6.4)
Viral load (oropharynx) at baseline	25 (23.1)	3 (18.8)	2 (7.4)	13 (32.5)	9 (19.1)
Anti-SARS-CoV-2 antibodies at baseline	26 (24.1)	2 (12.5)	7 (25.9)	11 (27.5)	12 (25.5)
Spirometry at three months	7 (6.5)	1 (6.2)	0	2 (5.0)	4 (8.5)
Diffusion capacity at three months	8 (7.4)	1 (6.2)	0	3 (7.5)	4 (8.5)
CAT-score at three months	4 (3.7)	1 (6.2)	0	2 (5.9)	1 (2.1)
Chest CT at three months	6 (5.6)	0	1 (3.7)	3 (7.5)	2 (4.3)
Biobanking during hospital admission	17 (15.7)	6 (23.0)		4 (12.5)	
Biobanking at three months	10 (9.3)	3 (11.5)		3 (9.4)	

SoC, standard of care. HCQ, hydroxychloroquine. BMI, body mass index. P/F ratio, arterial oxygen pressure (pO₂) divided by fraction of inspired oxygen (f_iO₂). ICU, intensive care unit. CRP, C-reactive protein. LDH, lactate dehydrogenase. CAT-score, COPD assessment test score. CT, computed tomography.

Supplementary Table 2. Association between symptoms assessed by CAT-score, DL_{CO}%, and chest CT findings compared with normal chest CT at three months after hospital admission for COVID-19.

Respiratory symptoms (CAT score > 10)	Coefficient estimate	95 % confidence interval
DL _{CO} %	< -0.01	(-0.03, 0.02)
Reversible CT changes (any)	-0.58	(-2.02, 0.71)
Irreversible CT findings (any)	0.43	(-0.41, 1.30)

CAT-score, the COPD assessment test score. DL_{CO}, diffusion capacity of the lung for carbon monoxide, in percent of predicted. CT, computed tomography. Reversible CT findings defined as any occurrence of ground-glass opacities or mosaic pattern on chest CT. Irreversible CT findings defined as any occurrence of parenchymal bands, reticular pattern, interlobular septal thickening, consolidations or bronchiectasis.